Arnau Montraveta

The Bruton Tyrosine Kinase (BTK) Inhibitor Acalabrutinib Demonstrates Potent On-Target Effects and Efficacy in Two Mouse Models of Chronic Lymphocytic Leukemia

Sarah E. M. Herman, Arnau Montraveta, Carsten Utoft Niemann et al. · Clinical Cancer Research · 2016 · 157 citations · Full text

Synergistic antitumor activity of lenalidomide with the BET bromodomain inhibitor CPI203 in bortezomib-resistant mantle cell lymphoma

Alexandra Moros, Vanina Rodríguez, Ifigènia Saborit-Villarroya et al. · Leukemia · 2014 · 100 citations

Hematological Malignancy, Lymphoid Neoplasia, Medicinal Chemistry +7

The γ-secretase inhibitor PF-03084014 combined with fludarabine antagonizes migration, invasion and angiogenesis in NOTCH1-mutated CLL cells

Mònica López‐Guerra, Sílvia Xargay‐Torrent, Laia Rosich et al. · Leukemia · 2014 · 69 citations · Full text

Signal Transduction, Signaling Pathway, Notch1-mutated Cll Cells +8

The splicing modulator sudemycin induces a specific antitumor response and cooperates with ibrutinib in chronic lymphocytic leukemia

Sílvia Xargay‐Torrent, Mònica López‐Guerra, Laia Rosich et al. · Oncotarget · 2015 · 66 citations · Full text

Mutations in the RAS-BRAF-MAPK-ERK pathway define a specific subgroup of patients with adverse clinical features and provide new therapeutic options in chronic lymphocytic leukemia

Neus Giménez, Alejandra Martínez‐Trillos, Arnau Montraveta et al. · Haematologica · 2018 · 59 citations · Full text